Outlook Therapeutics, Inc. OTLK

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Biologics License Application, or BLA, is currently under review at the U.S. Food and Drug Administration, or FDA, for the use of ONS-5010/LYTENAVA as a treatment for wet AMD in the United States. If approved by the FDA., our goal is to also launch directly in the United States as the first and only approved ophthalmic bevacizumab for the treatment of wet AMD. In addition to Europe and the United States., we may seek approval to launch ONS-5010/LYTENAVA the product in other markets. ONS-5010/LYTENAVA is manufactured in the United States.

Last close 0.52 2026-10-23
Market cap $126.4M 2026-06-30 share count
52-week range 0.16 - 2.54

Valuation FY2025 figures against the last close

P/S89.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.79

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.4M—————$8.1M$3.1M$3.8M$3.0M
Cost of revenue $1.4M—————————
Gross profit $57.2K—————————
R&D $27.2M$41.8M$26.5M$42.3M$39.0M$26.3M$23.8M$18.5M$23.8M$32.8M
SG&A $39.9M$29.9M$26.7M$20.7M$12.8M$10.0M$9.4M$14.2M$15.9M$21.6M
Total operating expenses ————$51.7M$36.8M$44.4M$32.7M$39.7M$54.3M
Operating income -$67.1M-$71.7M-$53.1M-$63.1M-$51.7M-$36.8M-$36.3M-$29.6M-$35.9M-$51.3M
Interest expense $283.1K$3.2M$2.5M$1.5M$936.1K$1.8M$3.5M$3.9M$5.6M$1.9M
Pre-tax income -$64.0M-$75.4M-$59.0M-$66.0M-$53.2M-$38.5M-$37.9M-$33.7M-$38.3M-$53.2M
Income tax $1.6M$2.8K$2.8K$2.8K$2.0K$3.3M$3.4M$3.6M$501.5K$103.0K
Net income -$62.4M-$75.4M-$59.0M-$66.1M-$53.2M-$35.2M-$34.5M-$30.1M-$38.8M-$53.3M
EPS, basic -1.79-4.06-4.72-0.31-0.35-0.67—-1.22-1.67-3.67
EPS, diluted -1.79-4.06-4.72-0.31-0.35-0.67-1.98-9.74-1.80-3.67
Shares, diluted (wtd. avg.) 34.8M18.5M12.5M212.1M152.7M72.6M—39.5M24.0M17.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $8.1M$14.9M$23.4M$17.4M$14.5M$12.5M$8.0M$1.7M$3.2M$2.4M
Receivables $1.5M—————————
Inventory $3.3M—————————
Total current assets $17.4M$27.4M$31.0M$27.5M$21.5M$17.9M$13.5M$3.3M$3.9M$5.7M
Property, plant and equipment ————$163.6K$327.2K$3.2M$18.5M$16.1M$18.7M
Total assets $18.6M$28.8M$32.3M$28.5M$22.8M$19.7M$17.1M$22.3M$20.7M$25.4M
Accounts payable $10.2M$8.0M$6.6M$3.5M$2.2M$2.4M$2.3M$3.6M$11.0M$5.1M
Short-term debt ——————$1.0M$66.5K$52.6K$586.5K
Total current liabilities $45.8M$42.6M$46.7M$19.7M$6.8M$15.9M$20.3M$32.0M$28.7M$20.4M
Long-term debt ——————$50.3K$98.5K$151.1K$2.2M
Total liabilities $50.8M$101.9M$46.7M$19.8M$18.2M$16.9M$27.9M$43.1M$51.5M$30.6M
Retained earnings -$605.7M-$543.3M-$467.9M-$408.9M-$342.9M-$289.7M-$254.5M-$216.3M-$186.2M-$147.4M
Total equity -$32.2M-$73.1M-$14.4M$8.7M$4.6M$2.8M-$16.1M-$25.5M-$33.7M-$5.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$51.8M-$68.8M-$43.0M-$56.7M-$54.3M-$31.8M-$32.3M-$33.0M-$15.5M-$45.5M
Depreciation and amortisation ———$163.6K$163.6K$219.4K$3.4M$3.1M$2.7M$2.4M
Stock-based compensation $8.9M$5.4M$5.5M$7.7M$4.9M$2.8M$1.3M$2.0M$8.6M$12.5M
Capital expenditure ——————$437.3K$2.8M$292.1K$1.1M
Investing cash flow —————-$900.0K-$437.3K-$2.8M-$292.1K-$1.1M
Financing cash flow $45.0M$60.3M$49.0M$59.6M$56.2M$37.2M$39.0M$34.4M$16.6M$39.9M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-25-123264.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M -75M -50M -25M 0 25M Revenue, FY2016: 3M Net income, FY2016: -53.3M Revenue, FY2017: 3.8M Net income, FY2017: -38.8M Revenue, FY2018: 3.1M Net income, FY2018: -30.1M Revenue, FY2019: 8.1M Net income, FY2019: -34.5M Net income, FY2020: -35.2M Net income, FY2021: -53.2M Net income, FY2022: -66.1M Net income, FY2023: -59M Net income, FY2024: -75.4M Revenue, FY2025: 1.4M Gross profit, FY2025: 57.2K Net income, FY2025: -62.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $3.0M $3.8M $3.1M $8.1M — — — — — $1.4M
Gross profit — — — — — — — — — $57.2K
Net income -$53.3M -$38.8M -$30.1M -$34.5M -$35.2M -$53.2M -$66.1M -$59.0M -$75.4M -$62.4M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%